Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia
Completed · Phase 2 · Has a placebo group
Conditions studied: Cognitive Impairment, Schizophrenia
In brief
The purpose of this study is to assess the safety and effects on electrical activity in the brain of an investigational drug (RL-007) for improving cognition in patients with schizophrenia
Key facts
- Study ID
- NCT04822883
- Run by
- Recognify Life Sciences
- People needed
- 37
- Starts
- 2021-04-26
- Expected to finish
- 2021-10-28
- Last updated by the study team
- 2022-04-27
Who can join
Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Collaborative Neuroscience Research — Long Beach, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.